Anti-amyloid immunotherapies such as aducanumab, lecanemab, and donanemab have shown promise in the treatment of early Alzheimer’s disease (AD). However, these effects remain below the established minimal clinically relevant values. Given the risk of amyloid-related imaging abnormalities (ARIA) that can, in some cases, hospitalize patients, the benefit/risk ratio of these drugs has been debated. Nicolas Villain, MD, PhD, AP-HP Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France, suggests future directions for anti-amyloid immunotherapies that could help to increase their meaningful clinical benefit. These include: longer follow-ups during clinical trials, identifying individuals that respond better to the drugs, and using anti-amyloid immunotherapies in combination with other therapies. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.